Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib as Induction and Maintenance Therapy in Stage III Unresectable EGFRm NSCLC (NEOLA)
NCT06194448Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Jul 2026
- Countries
- 9
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Apr 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06194448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194448.